Education
About Us
Working with TipRanks
Follow Us
Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
DWTX Stock Chart & Stats
$3.15
-$0.11(-4.15%)
At close: 4:00 PM EST
$3.15
-$0.11(-4.15%)
Day’s Range― - ―
52-Week Range$2.60 - $9.50
Previous CloseN/A
Volume14.38K
Average Volume (3M)1.54M
Market Cap
$92.86M
Enterprise Value-$4.64M
Total Cash (Recent Filing)$10.13M
Total Debt (Recent Filing)$174.78K
Price to Earnings (P/E)―
Beta2.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,401,554
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit157.61
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$13.50Price Target Upside328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutTopline results from the Phase 2b trial of Halneuron in chemotherapy-induced neuropathic pain could establish a clear regulatory pathway and enable meaningful market uptake in a space with no approved therapies.
Commercial Partnership PotentialStrong interest from major pharmaceutical companies in sodium-channel pain therapies signals attractive partnership and licensing opportunities that could accelerate commercialization and provide non-dilutive funding.
External Funding ValidationNational Cancer Institute funding for a clinical study of SP16 serves as external validation of the program and could advance clinical development without additional immediate company funding.
Bears Say
Development And Regulatory RiskValuation and outlook remain exposed to clinical, regulatory, commercial, collaboration and intellectual property risks that could hinder program advancement or future returns.
Financing RiskLimited company cash resources create a need for additional financing before key development milestones, increasing the risk of dilution or delayed programs.
Revenue And ProfitabilityAbsence of product revenues combined with ongoing net losses underscores an ongoing dependence on external funding and heightens execution risk for the business model.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $2.60 and its highest was $9.50 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $92.86M.
When is Dogwood Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Dogwood Therapeutics’s earnings last quarter?
Currently, no data Available
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 33,401,554 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (328.57% Upside)
$13.50 (328.57% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.36%
12-Months-Change
Fundamentals
Return on Equity
-66.07%
Trailing 12-Months
Asset Growth
-10.43%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$13.50
▲(328.57% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
74.31% Insiders
0.10% Mutual Funds
<0.01% Other Institutional Investors
25.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---